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Abstract All previous tudies of the localization of utrophin (the 
dystrophin-related protein) in muscle and other tissues have been 
performed only with antibodies against the C-terminal region of 
the protein. Since several short forms of dystrophin, the apo- 
dystrophins, are produced from the 3' end of the dystrophin gene, 
there is a possibility that similar short forms of utrophin exist and 
that these could be responsible for some of the many different 
localizations of 'utrophin' in muscle. We have produced a new 
panel of 15 mAbs against the N-terminal region of utrophin and 
we have used it together with mAbs against he C-terminal region 
to show that full-length utrophin is present at neuromuscular 
junctions, in nerves, blood vessels and capillaries in normal muscle 
and in the sarcolemma of patients with muscular dystrophy and 
dermatomyositis. However, two of the 15 mAbs also recognised 
ratlmouse utrophin and both of these detected an additional 
62 kDa protein on Western blots of rat C6 glioma cells. This 
potential 62 kDa 'apo-utrophin' was not detected in human cere- 
bral cortex, in rat Schwannoma cells nor in any of the non-nerve 
cells and tissues tested. 
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1. Introduction 
Dystrophin is a large, membrane-associated cytoskeletal pro- 
tein encoded by a gene on the X-chromosome and found mainly 
in muscle and brain [1,2]. The absence or malfunction of this 
protein is responsible for the Xp21-1inked muscular dystrophies 
(Duchenne and Becker types) [1,2]. Utrophin is a very similar 
protein encoded by an autosomal gene and found in nearly all 
tissues and cell types [3-5]. Both proteins have long rod-like, 
central helical regions separating C-terminal domains, which 
interact with transmembrane glycoproteins, from an N-termi- 
nal domain which interacts with actin, suggesting that they act 
as links between the cytoskeleton and the membrane [6,7]. In 
skeletal muscle, dystrophin is restricted to the sarcolemma but 
utrophin is found at neuromuscular junctions, in nerve fibres 
and in blood vessels and capillaries [4,8]. The dystrophin-asso- 
ciated glycoproteins in the sarcolemma interact extracellularly 
with the basement membrane protein, merosin (laminin-M) [9], 
whereas utrophin-associated glyeoproteins at neuromuscular 
junctions interact with agrin, a protein involved in synapse 
formation [10,11]. Several short forms of dystrophin, the apo- 
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dystrophins, have been shown to exist [12-17], though only the 
71 kDa apo-dystrophin-1 has a wide cell and tissue distribution. 
The apo-dystrophins may be particularly important for brain 
cell function [13] and all of the apo-dystrophins identified so far 
contain the cysteine-rich domain and the first half of the 
C-terminal domain of dystrophin, regions which are known to 
be important for membrane interaction [18,19]. Corresponding 
short forms of utrophin have not yet been identified; lower Mr 
bands on Western blots have certainly been detected using 
antibodies against the utrophin C-terminal domain [5], but 
these could be degradation products of the full-length utrophin 
which is found in all tissues (the identification of apo-dystro- 
phins was facilitated by the absence of full-length dystrophin 
from many cell lines and tissues containing apo-dystrophins 
[5]). 
Initially, only a part of the 3' end of utrophin cDNA was 
cloned and sequenced [3] and consequently all antibodies so far 
produced against utrophin have been directed against the 
C-terminal domain [4,8,20]. This leaves open the possibility that 
some of the minor localizations of utrophin identified with 
these antibodies, uch as nerves or capillaries, could be due to 
short C-terminal forms, analogous to the apo-dystrophins. 
Even the appearance ofutrophin in the sarcolemma of patients 
with Xp21-1inked muscular dystrophies or with inflammatory 
myopathies [21,22] could arguably be due to short forms. In- 
creases in the 400 kDa utrophin band have been reported on 
Western blots of Duchenne muscle [22], but some of this in- 
crease might be due to a higher proportion of blood vessels and 
other utrophin-containing components in dystrophic muscle. 
The recent cloning of the complete human utrophin cDNA [7] 
has enabled production of recombinant protein fragments of 
the N-terminal domain of utrophin. We have prepared a new 
panel of monoclonal antibodies (mAbs) against amino acids 
113-371 of utrophin and have used them to confirm that full- 
length, or near full-length, utrophin is found at all reported 
localities in normal muscle and in the sarcolemma ofdystrophic 
muscle. A possible 62 kDa short form of utrophin was found 
using the N-terminal mAbs, but only in glioma cells. 
2. Materials and methods 
2.1. mAb production 
Recombinant u rophin fragments (residues 1-261 and 113-371) were 
purified as described previously [23] and the latter was used to im- 
munise BALB/c mice. Two injections with adjuvant of 50 ¢tg, 4 weeks 
apart, were followed after 5-6 weeks by 150/tg intraperitoneally 2 and 
3 days before fusion of spleen cells with Sp2/O myeloma cells. Two 
separate fusions produced 7 and 8 cloned hybridoma lines respectively. 
Culture supernatants were screened against the recombinant antigen by 
ELISA and positive wells were screened further against full-length 
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utrophin on Western blots of human lung extracts. A further selection 
was then applied by immunofluorescence microscopy on normal 
human muscle frozen sections with screening for binding to blood 
vessels (a site of utrophin localization; see Fig. 1) but not to the sar- 
colemma (the site of dystrophin localization). 
2.2. Western blotting 
Tissue samples or cell pellets were sonicated and boiled in 4 vols. of 
SDS sample buffer (2% SDS, 10% glycerol, 5% 2-mercaptoethanol, 
50 mM Tris-HC1, pH 6.8). After centrifugation at 100,000 x g for 20 
min., extracts were subjected to SDS-PAGE. Electrophoretic blotting 
onto nitrocellulose sheets in the presence of 0.003% SDS and develop- 
ment with mAbs and the Vectastain Elite second antibody system has 
been described elsewhere [4]. Diffusion blotting is performed by im- 
mersing the gel/blot assembly vertically in 50 mM NaC1, 2 mM EDTA, 
10 mM Tris-HC1 pH 7.0 for 18-36 h with stirring [24]. Prestained Mr 
markers were from Sigma. 
2.3. Immunohistoehemistry andELISA 
Immunohistochemistry of frozen muscle sections using a biotin- 
avidin method with horseradish peroxidase has been described else- 
where [21]. The enzyme-linked immunosorbent assay (ELISA), using 
antigen-coated 96-well microtitre plates and peroxidase-labelled anti- 
(mouse Ig) as second antibody has been described elsewhere [25]. 
3. Results 
Table 1 shows 15 mAbs  prepared against amino-acids 113- 
371 o f  utrophin.  The mAbs  were selected ur ing screening for 
lack o f  cross-react ion with dystrophin.  Only two o f  the 15 
mAbs  cross-reacted with rat /mouse utrophin  (Table 1). Only 
three o f  the 15 mAbs  bound to utrophin residues 1-261 in an 
EL ISA  assay. Since residues 1-261 comprise nearly all o f  the 
N-terminal  domain ,  it is likely that most  o f  the other 12 mAbs  
require, or are directly solely against, the start o f  the rod do- 
main. There are 4 mAbs  in Table 1 which do not  recognise 
ut rophin  on Western blots, though they do recognise UTR113-  
371 in EL ISA;  it may be that they recognise some conformat ion  
C-terminal 
Table 1 
15 mAbs against he utrophin N-terminal region (aminoacids 113-371) 
Antibody 
Binding to 
Clone Ig sub- Utrophin Rat UTR1- 
No. class Utophin 261 
(blots) (blots) (ELISA) 
MANNUT1 3B6 G1 + + + + - 
MANNUT2 5C9 G2b + + + + - 
MANNUT3 4E3 G2b + + + - + + 
MANNUT4 6H4 G2a + - + + 
MANNUT5 8C 11 G 1 + - - 
MANNUT6 10D4 G2a + + - - 
MANNUT7 6A 10 G 1 - - - 
MANNUT8 10A7 G2a + + + - - 
MANNUT9 7C11 G1 - - - 
MANNUT10 3C10 n.d. + + + - - 
MANNUT11 3B3 G1 + + + - - 
MANNUT12 4B12 G2a + + - - 
MANNUT 13 2A5 G2a - - - 
MANNUT14 8A3 G2b + - + 
MANNUT15 5El0 G2b - - - 
All mAbs bound to UTR113-371 in ELISA and none of the mAbs 
bound to dystrophin on Western blots. Binding on blots was deter- 
mined using extracts of human lung and, for rat utrophin, C6 glioma 
cells. Ig subclass was determined using a mouse isotyping kit (Serotec). 
o f  the recombinant  ant igen which is not  shared by utrophin 
itself. 
Fig. la  shows that both N-terminal  and C-terminal  utrophin 
mAbs  give the same immunohis tochemica l  l bell ing of  nerve 
fibres, b lood vessels (arteries and veins) and capil laries in a 
normal  human muscle section and that they do not  label the 
sarcolemma. Fig. 1 b shows that both  mAbs  label a neuromus-  
cular junct ion.  This suggests that ful l- length utrophin  is present 
at all these sites, rather  than any short  form. Similarly, Fig. 2 
shows that the utrophin  found in the sarco lemma in Duchenne 
N-terminal 
Normal 
muscle 
NMJ 
Fig. 1. N-terminal and C-terminal utrophin mAbs recognize the same structures in normal muscle sections. In the upper figure (magnification 700 x), 
major blood vessels are labelled (upper left) together with a nerve fibre (arrow, lower left) and capillaries (right); the sarcolemma of the muscle fibres 
is not labelled (right). In the lower figure (magnification 1000x), a neuromuscular junction (NMJ) is labelled by both mAbs. 
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C-terminal N-terminal 
DMD 
Dermato 
Fig. 2. In Duchenne muscular dystrophy (DMD) and dermatomyositis (Dermato), the sarcolemma is labelled by both N-terminal and C-terminal 
utrophin mAbs. Membrane labelling is somewhat weaker in an area of regeneration (~) (magnification 500x). 
muscular dystrophy (DMD; Fig. 2a) and in dermatomyositis 
(Fig. 2b) is also full-length, or near full-length. In DMD, all 
fibres are labelled, though smaller, regenerating fibres are 
weaker, while in dermatomyositis, sarcolemmal utrophin la- 
belling is more variable, most large fibres and some small fibres 
being utrophin-positive in Fig. 2b [21]. 
Protein bands of lower Mr than utrophin are often detected 
with C-terminal utrophin mAbs on Western blots [5]. It is 
impossible to say, however, whether these smaller proteins are 
the products of different mRNA transcripts of the utrophin 
gene, analogous to the apo-dystrophins, or whether they are 
simply degradation products of utrophin. Using our new panel 
of mAbs on Western blots, we found a 62 kDa protein in rat 
C6 glioma cells but not in other cell lines or in human tissues 
(Fig. 3). We feel this is unlikely to be a degradation product of 
utrophin because preliminary studies have shown that a corre- 
sponding mRNA of appropriate size also exists in C6 glioma 
cells (Zuellig and Davies, unpublished ata). The specificity of 
the protein for C6 glioma cells also argues against its being a 
degradation product. In human brain extracts (Fig. 3b), we 
could detect only full-length utrophin (the two lower Mr bands 
being cross-reactions of the second antibody detection system). 
We found that the 62 kDa protein is best transferred by diffu- 
sion blotting (Fig. 3a) though the higher Mr utrophin is not 
transferred under these conditions. The 62 kDa protein is still 
detectable after electrophoretic blotting, however, together 
with utrophin itself (Fig. 3c). The same 62 kDa protein is 
detected by two different mAbs, so it is unlikely to be a cross- 
reactive antigen unrelated to utrophin. 
4. Discussion 
We have prepared a panel of 15 mAbs against part of the 
N-terminal region of utrophin (amino acids 113-371). Residues 
113-371 of utrophin comprise the C-terminal half of the actin 
binding domain and the beginning of the spectrin-like coiled 
coil repeats. Utrophin 113-371 does bind actin (Kd 275/zM; 
[23]) but rather weakly compared to the complete actin binding 
domain, residues 1-261 (K d 19/2M; [23]). It is likely, as with 
dystrophin, that more than one region in the linear sequence 
of utrophin contributes to actin binding [23]. 
Utrophin at the neuromuscular junction and in nerves, blood 
vessels and capillaries, as well as in the sarcolemma of patients 
with certain myopathies, is the full-length protein, since mAbs 
directed against he N- and C-termini give the same labelling 
pattern. This does not, however, exclude the possibility of a 
contribution to the labelling from apo-utrophins. The detection 
of a possible 62 kDa N-terminal short form of utrophin in a rat 
glioma cell line shows that the problem of short forms may well 
be a real one, though, unlike the well-characterized apo-dystro- 
phins, they have not been shown to be widely present in human 
tissues. 
The observation that utrophin appears in the extra-junc- 
tional sarcolemma only in Duchenne/Becker muscular dystro- 
phies (where dystrophin is absent or reduced) and in inflamma- 
tory myopathies (where dystrophin levels are normal) suggests 
a possible role for the inflammatory esponse in inducing utro- 
phin. Mast cells are present in muscle in Duchenne MD and 
inflammatory myopathies, but they may be localised to areas 
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(a) Mr Gli Sp2P388 
62kD 
(b) 
Brain Brain 
ad. foet Mr ad. foet 
Dystrophin at the sarcolemma interacts with extracellular lam- 
inin via a dystroglycan complex (extracellular 156DAG and 
transmembrane 43DAG) [9] and a similar utrophin complex 
interacts with extracellular agrin at neuromuscular junctions 
[10]. It is not yet known whether the same or another complex 
of extracellar and transmembrane proteins is involved in medi- 
ating the appearance of utrophin in the myopathic sarcolemma; 
there is some correlation between the distributions and levels 
of 43DAG and utrophin labelling, but it is not always clear-cut 
[28]. 
This panel ofmAbs will be useful for future screening for new 
utrophin isoforms and products of mutations in the utrophin 
gene. 
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Fig. 3. A 62 kDa protein band is detected by N-terminal utrophin mAbs 
in rat C6 glioma cell extracts (Gli) but not in in other human tissues 
or cell lines. Diffusion blotting was used in (a) to enhance transfer of 
low Mr proteins and utrophin is not transferred for this reason. Non- 
specific reactions of the second antibody detection system are shown 
by asterisks and can be identified by control experiments in which the 
primary anti-utrophin mAb (Mannutl) is omitted (b). The cell extracts 
in (c) are from human skin fibroblasts (Fibs), rat L6 myoblasts (L6) and 
C6 glioma cells (Gli) and the tissue xtracts are adult human. Utrophin 
(395 kDa) is present in all extracts. The 62 kDa protein was also 
undetectable in HeLa and SWA Schwannoma cells (not shown). 
of necrosis and regeneration [26,27], so they are unlikely to 
account for the uniform effect on all muscle fibres in Duchenne 
and Becker MDs [21]. The possibility, however, of a common 
mediator of utrophin induction, such as elevated calcium, in the 
two types of muscle disease cannot be ruled out at this stage. 
The molecular mechanism by which utrophin interacts with 
the dystrophic sarcolemma is not yet clearly established. 
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